Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Operating Income | -57M | -54M | -31M | -31M | -24M |
| EBITDA | -57M | -46M | -31M | -31M | -24M |
| Net Income | -51M | -46M | -28M | -30M | -24M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$6.68
+2.30% today
1Y Change
-20.10%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sagimet Biosciences Inc. (SGMT) is a Healthcare stock with a market cap of $240.00M and listed on NASDAQ. The stock last traded around $6.68 and down 20.1% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -9.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -9.0%, free cash flow -7.6% with operating margin 0.0% and ROIC -51.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SGMT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGMT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGMT Max Drawdown
-55.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SGMT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$24.4M
+19.9% YoY
Free Cash Flow
-$21.7M
+11.4% YoY
Revenue Growth
+0.0%
EPS Growth
-9.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Operating Income | -57M | -54M | -31M | -31M | -24M |
| EBITDA | -57M | -46M | -31M | -31M | -24M |
| Net Income | -51M | -46M | -28M | -30M | -24M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35M | 76M | 75M | 158K | 57M |
| Total Assets | 116M | 160M | 97M | 33M | 59M |
| Total Liabilities | 5M | 4M | 6M | 220M | 217M |
| Shareholder Equity | 111M | 156M | 91M | -187M | -158M |
| Total Debt | 78K | 78K | 65K | 211K | 348K |
| Net Debt | -35M | -76M | -75M | 53K | -56M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+11.4% YoY
Capital Expenditures
0
Free Cash Flow
22M
+11.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-40.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.